Incidence and outcome of TCF3-PBX1-positive acute lymphoblastic leukemia in Austrian children

Haematologica

Volumn 92, Issue 11, 2007, Pages 1561-1564

  Kager, Leo ^a   Lion, Thomas ^b   Attarbaschi, Andishe ^a   Koenig, Margit ^b   Strehl, Sabine ^b   Haas, Oskar A ^a   Dworzak, Michael N ^a   Schrappe, Martin ^c   Gadner, Helmut ^a,b   Mann, Georg ^a  

^a ST ANNA CHILDREN S HOSPITAL   (Austria)

^b CHILDREN'S CANCER RESEARCH INSTITUTE   (Austria)

^c UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

Author keywords

Acute lymphoblastic leukemia; Outcome; TCF3 PBX1

Indexed keywords

ANTINEOPLASTIC AGENT; HYBRID PROTEIN; METHOTREXATE; PREDNISONE; TCF3 PBX1 PROTEIN; TRANSCRIPTION FACTOR E2A; TRANSCRIPTION FACTOR PBX1; UNCLASSIFIED DRUG;

ACUTE LYMPHOBLASTIC LEUKEMIA; ARTICLE; AUSTRIA; CANCER SURVIVAL; CHILDHOOD LEUKEMIA; LEUKEMIA REMISSION; OUTCOME ASSESSMENT; PROGNOSIS; SINGLE DRUG DOSE; SURVIVAL RATE;

ADOLESCENT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ASPARAGINASE; AUSTRIA; BASIC HELIX-LOOP-HELIX TRANSCRIPTION FACTORS; CHILD; CHILD, PRESCHOOL; DAUNORUBICIN; DNA-BINDING PROTEINS; HUMANS; INCIDENCE; INFANT; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PREDNISONE; PROTO-ONCOGENE PROTEINS; SURVIVAL RATE; TREATMENT OUTCOME; VINCRISTINE;

EID: 36348988513     PISSN: 03906078     EISSN: None     Source Type: Journal    
DOI: 10.3324/haematol.11239     Document Type: Article

References (20)

1. Hunger SP. Chromosomal translocations involving the E2A gene in acute lymphoblastic leukemia: clinical features and molecular pathogenesis. Blood 1996;87:1211-24.
2. Pui CH, Sandlund JT, Pei D, Rivera GK, Howard SC, Ribeiro RC, et al. Results of therapy for acute lymphoblastic leukemia in black and white children. JAMA 2003;290: 2001-7.
3. Shearer BM, Flynn HC, Knudson RA, Ketterling RP. Interphase FISH to detect PBX1/E2A fusion resulting from the der(19)t(1;19)(q23;p13.3) or t(1;19)(q23;p13.3) in paediatric patients with acute lymphoblastic leukaemia. Br J Haematol 2005;129:45-52.
4. Carroll AJ, Crist WM, Parmley RT, Roper M, Cooper MD, Finley WH. Pre-B cell leukemia associated with chromosome translocation 1;19. Blood 1984;63:721-4.
5. Crist WM, Carroll AJ, Shuster JJ, Behm FG, Whitehead M, Vietti TJ, et al. Poor prognosis of children with pre-B acute lymphoblastic leukemia is associated with the t(1;19) (q23;p13): a Pediatric Oncology Group study. Blood 1990;76:117-22.
6. Seeker-Walker LM, Berger R, Fenaux P, Lai JL, Nelken B, Garson M, et al. Prognostic significance of the balanced t(1;19) and unbalanced der(19)t(1;19) translocations in acute lymphoblastic leukemia. Leukemia 1992;6:363-9.
7. Pui CH, Raimondi SC, Hancock ML, Rivera GK, Ribeiro RC, Mahmoud HH, S, et al. Immunologic, cytogenetic, and clinical characterization of childhood acute lymphoblastic leukemia with the t(1;19) (q23; p13) or its derivative. J Clin Oncol 1994;12: 2601-6.
8. Raimondi SC, Behm FG, Roberson PK, Williams DL, Pui CH, Crist WM, et al. Cytogenetics of pre-B-cell acute lymphoblastic leukemia with emphasis on prognostic implications of the t(1;19). J Clin Oncol 1990;8: 1380-8.
9. Uckun FM, Sensel MG, Sather HN, Sensel MG, Kraft P, Steinherz PG, et al. Clinical significance of translocation t(1;19) in childhood acute lymphoblastic leukemia in the context of contemporary therapies: a report from the Children's Cancer Group. J Clin Oncol 1998;16:527-35.
10. Schrappe M, Reiter A, Ludwig WD, Harbott J, Zimmermann M, Hiddemann W, et al. Improved outcome in childhood acute lymphoblastic leukemia despite reduced use of anthracyclines and cranial radiotherapy: results of trial ALL-BFM 90. German-Austrian-Swiss ALL-BFM Study Group. Blood 2000;95:3310-22.
11. Schrappe M, Reiter A, Zimmermann M, Harbott J, Ludwig WD, Henze G, et al. Long-term results of four consecutive trials in childhood ALL performed by the ALL-BFM study group from 1981 to 1995. Berlin-Frankfurt-Munster. Leukemia 2000;14:2205-22.
12. Gabert J, Beillard E, van der Velden VH, Bi W, Grimwade D, Pallisgaard N, et al. Standardization and quality control studies of 'real-time' quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia - a Europe Against Cancer program. Leukemia 2003;17: 2318-57.
13. van der Burg M, Poulsen TS, Hunger SP, Beverloo HB, Smit EM, VangNielsen K, et al. Split-signal FISH for detection of chromosome aberrations in acute lymphoblastic leukemia. Leukemia 2004;18:895-908.
14. Izraeli S, Henn T, Strobl H, Ludwig WD, Kovar H, Haas OA, et al. Expression of identical E2A/PBX1 fusion transcripts occurs in both pre-B and early pre-B immunological subtypes of childhood acute lymphoblastic leukemia. Leukemia 1993; 7:2054-6.
15. Stanulla M, Schaeffeler E, Flohr T, Cario G, Schrauder A, Zimmermann M, et al. Thiopurine methyltransferase (TPMT) genotype and early treatment response to mercaptopurine in childhood acute lymphoblastic leukemia. JAMA 2005; 293:1485-9.
16. Paulsson K, Horvat A, Fioretos T, Mitelman F, Johansson B. Formation of der(19)t(1;19)(q23;p13) in acute lymphoblastic leukemia. Genes Chromosomes Cancer 2005;42:144-8.
17. Baruchel A, Chevret S, Auvrignon A, Ballerini P, Michel G, Gabert J, et al. A plateau after 30 months of follow-up in B-lineage childhood acute lymphoblastic leukemia with t(1;19) (q23;p13)/E2A-PBX1? Blood Suppl 2005;106[Abstract 1441].
18. Maloney KW, Shuster JJ, Murphy S, Pullen J, Camitta BA. Long-term results of treatment studies for childhood acute lymphoblastic leukemia: Pediatric Oncology Group studies from 1986-1994. Leukemia 2000;14:2276-2285.
19. Eden OB, Harrison G, Richards S, Lilleyman JS, Bailey CC, Chessells JM, et al. Long-term follow-up of the United Kingdom Medical Research Council protocols for childhood acute lymphoblastic leukaemia, 1980-1997. Medical Research Council Childhood Leukaemia Working Party. Leukemia 2000;14:2307-320.
20. Hunger SP, Fall MZ, Camitta BM, Carroll AJ, Link MP, Lauer SJ, et al. E2A-PBX1 chimeric transcript status at end of consolidation is not predictive of treatment outcome in childhood acute lymphoblastic leukemias with a t(1;19)(q23;p13): a Pediatric Oncology Group study. Blood 1998;91:1021-8.